President & Chief Executive Officer
Chief Scientific Officer
Vice President Discovery & Translational Science
President & Chief Executive Officer
Kathleen Fanning is President and Chief Executive Officer at Mozart Therapeutics. She brings more than 35 years of leadership experience in both public and private biopharmaceutical companies. Prior to Mozart, she served as President and CEO at Nohla Therapeutics, a clinical-stage cell therapy company. During her tenure at Nohla, her strategic and operational leadership transitioned the company from an academic focus to a fully integrated business. Prior to Nohla, Ms. Fanning was Chief Operating Officer at VentiRx, and played an instrumental role in the strategic collaboration and company acquisition by Celgene. She has held senior leadership roles at Cell Therapeutics Inc., and CellPro Inc. that included Vice President of Business Development and Vice President of Sales and Marketing where she built and led global sales and marketing organizations. She also spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca) holding positions of ascending responsibility across sales, marketing and early commercial development. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio. She serves as a Director of Egenesis Bio and Walden Biosciences.
Kristine Swiderek PhD
Chief Scientific Officer
Kristine Swiderek is Chief Scientific Officer at Mozart Therapeutics. She has more than 25 years of research and leadership experience in the biopharmaceutical industry and a proven track record of discovering and developing a wide variety of protein therapeutics. Prior to Mozart, Dr. Swiderek was Senior VP of Research at Alpine Immune Sciences, where she was instrumental in building a pipeline advancing protein-based immunotherapies for treatment of autoimmune disease and cancer. As Chief Scientific Officer at OncoResponse and Theraclone, she developed and executed research and development strategies. She formed multiple R&D partnerships, advanced several therapeutic candidates into the clinic and was instrumental in the spin-out of OncoResponse. She has also held several positions of increasing responsibility at ZymoGenetics, a publicly-listed company where she advanced over a dozen candidates into clinical development. Dr. Swiderek received her Ph.D. in Protein Biochemistry from the Ruhr-Universität in Bochum, Germany. She completed her postdoctoral studies at City of Hope, Duarte, CA and at Indiana University, Indianapolis, IN. She is the author of over 60 peer-reviewed articles and manuscripts.
Courtney Crane PhD
Vice President Discovery & Translational Science
Courtney Crane is the Vice President of Discovery and Translation at Mozart Therapeutics. Previously as an Associate Professor at the University of Washington, she established and mentored a research team that developed novel cell therapy platforms using gene edited natural killer cells and macrophages for the delivery of several classes of soluble proteins, including cytokines, bispecific T cell engagers, and full-length antibodies. During this time, she established several industry sponsored research programs, and successfully out-licensed multiple technologies developed in her lab to a publicly-traded biotech company. Dr. Crane received her Ph.D. in Immunology from the University of Virginia under the mentorship of Dr. Margo Roberts, and completed her postdoctoral research at the University of California, San Francisco studying the dysregulation of immune responses in brain tumors with Drs. Lewis Lanier and Andrew Parsa before starting an independent research program as academic faculty. She is an author on over 30 peer-reviewed publications and patents and continues her role as strategic advisor for public and privately-held biotechnology industry partners.
Board of Directors
Steven Gillis PhD
Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a Founder and Director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its Chairman, until its acquisition by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was Founder and Director of Immunex Corporation, which was acquired by Amgen for $16B. During his tenure, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. He was interim Chief Executive Officer of Immunex following its majority purchase by American Cyanamid Company, and was also a Board Member. He is credited as a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, Prokine and Enbrel, and the regulatory approval of Bexxar and the novel vaccine adjuvant, MPL. Dr. Gillis received his B.A. from Williams College and his Ph.D. from Dartmouth College. He is an immunologist by training with over 300 peer-reviewed publications, and serves as a Director or Chairman in multiple private and publicly-held biotechnology companies.
Tom Daniel MD
Tom Daniel has more than 20 years of experience leading and building research and development organizations and leading investments in new companies at the forefront of innovative applications of science and healthcare. During the past five years, he served as a Venture Partner at ARCH Venture Partners, following a decade as President of Global Research and Early Development at Celgene Corporation. He previously served in senior leadership roles at AmbRx, Amgen and Immunex. Tom currently serves as Chair at LocanaBio, and is Director at a number of private and publicly-held companies. He is Chair of Life Science Cares-San Diego, a Trustee of Reed College, a Director at Scripps Research and Chair of the Board of Overseers, and is a senior advisor to several private biotechnology companies. A nephrologist and former academic investigator, he was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. Dr. Daniel received his M.D. from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed his residency in Internal Medicine at Massachusetts General Hospital.
Peter Dudek PhD
Peter Dudek has over 13 years of experience in the life sciences industry spanning research, company building, and corporate and traditional venture, across a broad range of therapeutic areas and modalities. He currently serves as President and Managing Partner of Merck’s MRL Ventures (MRLV) Fund and is responsible for its investments in Ambagon Therapeutics, Caraway Therapeutics, Carisma Therapeutics, HotSpot Therapeutics, Imago Biosciences (NASDAQ: IMGO), Kymera Therapeutics (NASDAQ: KYMR), Xilio Therapeutics, and Mozart Therapeutics. Prior to MRLV, he was a Principal with Wellington Partners, a European venture fund with more than $1B under management. He has held roles at Entrepreneurs Fund and at the corporate venture arm of Novartis. Dr. Dudek received his B.Sc. with Honors from the University of British Columbia, and was a research associate at the BC Centre for Disease Control. He obtained his Ph.D. from the University of Geneva, and was a Postdoctoral Fellow at the University of Oxford.
Julie Gilmore PhD
Julie Gilmore is the Site Head and Chief Operating Officer for Lilly Gateway Labs, a shared innovation lab located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. She joined Eli Lilly after receiving her Doctorate in Membrane Biophysics from Purdue University and her Postdoctoral Fellowship in Drug Transport from Indiana University School of Medicine. During her 20-year plus career at Lilly, Julie has held several leadership and scientific positions across research and drug development, including Head of Information Sciences and Clinical Operations for Lilly Europe, Global Head of Scientific Communications, and most recently, Senior Director of Portfolio Management for the Neurodegeneration and Pain Early Phase Portfolio. Julie is on the Board of Governors for BioCom and the Board of Directors for California Life Sciences. She also serves as a mentor and advisor to several university graduate school programs including locally at UCSF.
Lucio Iannone PhD
Lucio Iannone is Vice President of Venture Investments at Leaps by Bayer, the investment arm of the global life sciences company Bayer. Dr. Iannone is responsible for developing investment cases and deal execution and managing the health investment team. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science. As an investor, Lucio is also serving as board member for Khloris Biosciences, Pyxis Oncology, Immunitas Therapeutics, eGenesis, Mozart Therapeutics and Axxam. Before joining Leaps by Bayer, he had held several senior roles in biotechnology companies and venture capital firms. He received his M.Sc in molecular biology from Cambridge university and Ph.D. in Medicine from Imperial College in London. Dr. Iannone’s expertise is in cell and gene therapy, and in several therapeutic fields such as oncology, immunology and gene therapy.
Henrijette Richter is Managing Partner at Sofinnova Partners. She joined the firm in 2014. Prior to that, she was part of the team that founded Novo Seeds in 2007, and as an Investment Director, was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris). Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts. Her investments and board involvements include Asceneuron, Delinia (sold to Celgene), iOmx Therapeutics, Muna Therapeutics, Nodthera, Nitrome Biosciences, and Twentyeight-Seven Therapeutics.
SCIENTIFIC Advisory Board
Mark Davis PhD
Mark M. Davis is the Director of the Stanford Institute for Immunology, Transplantation and Infection (ITI), the Avery Family Professor of Immunology, and a Howard Hughes Medical Institute Investigator. He is well known for identifying many of the T-cell receptor genes, which govern specificity for T cells, and his work characterizing their binding properties and behavior on cell surfaces, including the demonstration that T cells can detect and respond to even a single antigenic peptide-MHC complex. He also developed a novel way of labeling specific T lymphocytes (“peptide-MHC tetramers”), which is widely used in both clinical and basic immunology studies. His current research interests focus on human immunology, specifically a “systems level” understanding of an immune response to vaccination, infection and autoimmunity, as well as methods to better understand human T cell responses. He received a B.A. from Johns Hopkins University and a Ph.D. from the California Institute of Technology with Leroy Hood. He was also a postdoctoral and staff fellow William Paul at the Laboratory of Immunology at the NIH before joining the Stanford faculty. He has received many honors and awards, including the Gairdner Award, the Paul Ehrlich Award and the King Faisal Prize, among others. He is also a member of the National Academy of Sciences, the National Academy of Medicine, and the Royal Society of London.
K. Christopher Garcia PhD
K. Christopher Garcia is a Professor of Molecular and Cellular Physiology and Structural Biology at the Stanford University School of Medicine. Dr. Garcia’s research interests reside at the cell surface, and his laboratory is investigating structural and functional aspects of cell surface receptor recognition and activation, in receptor-ligand systems with relevance to human health and disease. After two years of post-doctoral work at Genentech. under Dr. David Goeddel in the Department of Molecular Biology, where he learned the emerging technologies of protein engineering and recombinant protein expression, Dr. Garcia moved to a second post-doctoral fellowship at The Scripps Research Institute in the laboratory of Professor Ian Wilson, where he succeeded in determining the first crystal structures of the T cell receptor and then its complex with peptide-MHC. Dr. Garcia started his lab at Stanford University School of Medicine in 1999, where he also became an Investigator in the Howard Hughes Medical Institute. He received his B.S. in Biochemistry from Tulane University, and his Ph.D in Biophysics from Johns Hopkins University. Dr. Garcia was elected to the National Academy of Sciences in 2012, and the National Academy of Medicine in 2016.
Calvin Kuo MD PhD
Calvin Kuo is the Maureen Lyles D’Ambrogio Professor of Medicine (Hematology) at Stanford University School of Medicine. His research focuses on cancer modeling in 3D organoid cultures, biology of intestinal and lung stem cell populations, and molecular regulation of angiogenesis and the blood-brain barrier. He received an A.B., Harvard College, Biochemical Sciences and his M.D./Ph.D., at Stanford University Medical School, with a focus on Cancer Biology. He conducted his residency at Brigham and Women’s Hospital, Internal Medicine, and a Fellowship at Dana-Farber/Partners in Adult Oncology. He is an elected member of the Association of American Physicians, American Society for Clinical Investigation and AAAS.
Michael Rosenblum MD PhD
Michael Rosenblum is Professor of Dermatology and Vice Chair of Research at the University of California San Francisco (UCSF) and is formally trained as an immunologist and a board-certified dermatologist. He graduated from UCSF’s prestigious Physician-Scientist Training Program in Dermatology and is the recipient of several distinguished awards, including the NIH’s New Innovator Award and a Burroughs Wellcome Career Development Award for Medical Scientists. The central focus of Dr. Rosenblum’s research is to understand the fundamental mechanisms of how immune responses are regulated and how this knowledge can be exploited for therapeutic benefit. Recent research has examined the biology of Regulatory T cells and Effector T cells resident within skin, humanized mouse models for studying the immunology of skin, and the interaction of the skin microbiome with the immune system. He was the scientific co-founder of Delinia Bio, which was acquired by Celgene. He is also co-founder of TRex Bio and Sitryx Bio, and has authored more than 85 basic science research papers. He received his M.D./Ph.D. from the Medical College of Wisconsin. He is a member of the American Association of Immunologists, Society for Investigative Dermatology, American Academy of Dermatology and Federation of Clinical Immunology Societies.
Building on seminal work of its scientific founders, Mozart Therapeutics is capitalizing on a novel CD8 T regulatory cell network to develop innovative disease-modifying therapies for autoimmune and inflammatory diseases.
Our advancing pipeline of first-in-class ‘CD8 Treg cell modulators’ are designed to restore durable immune balance and avert the progressive damage caused by pathogenic immune responses.
To date, we’ve demonstrated that CD8 T regulatory cells are selective and function specifically to eliminate pathogenic CD4 T cells and other pathogenic immune cells. The dysregulation of this T cell network is a root cause for the onset and severity of autoimmune and inflammatory disease and pathology.
Our targeted CD8 Treg cell modulators work to counteract the pro-inflammatory autoimmune response cascade in order to delay onset, reduce severity, and potentially reverse the course of disease.
CD8 T regulatory cells play a key role in selectively regulating auto-reactive and pathogenic CD4 T cells and other immune cells. In autoimmune disorders, this network is dysregulated, causing a downstream cascade of inflammatory events that result in tissue destruction.
We are targeting the CD8 T regulatory cell network to counteract early events in the inflammatory cascade. Therapeutic modulation of the CD8 T regulatory cell network is designed to restore CD8 T regulatory cell functions to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and inflammatory diseases.
We are building a robust pipeline of disease-modifying therapies that modulate the CD8 T regulatory cell network to target a root cause for a wide range of diseases. Our lead program is a first-in-class therapeutic candidate for the treatment of celiac disease, inflammatory bowel disease and other autoimmune diseases.
At Mozart Therapeutics, we are working in concert to discover, develop and commercialize breakthrough treatments to positively impact the lives of patients with autoimmune or inflammatory disease. If you are interested in being a part of our dedicated team, we would like to hear from you!
To be considered for a position at Mozart Therapeutics, please submit your resume and cover letter to firstname.lastname@example.org.